Evidence map›Paper›PMID 34333724›Full record

ArticleNeurogenetics2021

A founder mutation in the GMPPB gene [c.1000G > A (p.Asp334Asn)] causes a mild form of limb-girdle muscular dystrophy/congenital myasthenic syndrome (LGMD/CMS) in South Indian patients.

Kiran Polavarapu, Aradhna Mathur, Aditi Joshi, Saraswati Nashi, Veeramani Preethish-Kumar, Mainak Bardhan, Pooja Sharma, Shaista Parveen, Malika Seth, Seena Vengalil and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurogenetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. MICU1 related myopathy - a rare report from India.Journal of neuromuscular diseases · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 4 countries.

Kiran Polavarapu *Department of Neurology, National Institute of Mental Health And Neurosciences (NIMHANS), Bengaluru, 560029, India.
Aradhna Mathur *CSIR-Institute of Genomics and Integrative Biology, Mall Road, Delhi, 110025, India.
Aditi JoshiCSIR-Institute of Genomics and Integrative Biology, Mall Road, Delhi, 110025, India.
Saraswati NashiDepartment of Neurology, National Institute of Mental Health And Neurosciences (NIMHANS), Bengaluru, 560029, India.
Veeramani Preethish-KumarDepartment of Neurology, National Institute of Mental Health And Neurosciences (NIMHANS), Bengaluru, 560029, India.
Mainak BardhanDepartment of Neurology, National Institute of Mental Health And Neurosciences (NIMHANS), Bengaluru, 560029, India.
Pooja SharmaCSIR-Institute of Genomics and Integrative Biology, Mall Road, Delhi, 110025, India.
Shaista ParveenCSIR-Institute of Genomics and Integrative Biology, Mall Road, Delhi, 110025, India.
Malika SethCSIR-Institute of Genomics and Integrative Biology, Mall Road, Delhi, 110025, India.
Seena VengalilDepartment of Neurology, National Institute of Mental Health And Neurosciences (NIMHANS), Bengaluru, 560029, India.
Tanushree ChawlaDepartment of Neurology, National Institute of Mental Health And Neurosciences (NIMHANS), Bengaluru, 560029, India.
Leena ShingaviDepartment of Neurology, National Institute of Mental Health And Neurosciences (NIMHANS), Bengaluru, 560029, India.
Uzma ShamimCSIR-Institute of Genomics and Integrative Biology, Mall Road, Delhi, 110025, India.
Sushmita NayakCSIR-Institute of Genomics and Integrative Biology, Mall Road, Delhi, 110025, India.
A VivekanandCSIR-Institute of Genomics and Integrative Biology, Mall Road, Delhi, 110025, India.
Ana TöpfInstitute of Genetic Medicine, Newcastle University, New castle Upon Tyne, NE1 3BZ, UK.
Andreas RoosDepartment of Neuropediatrics, University Hospital Essen, 45147, Essen, Germany.
Rita HorvathDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 1TN, UK.
Hanns LochmüllerChildren's Hospital of Eastern Ontario Research Institute, Ottawa, K1H 5B2, Canada.
Bevinahalli NandeeshDepartment of Neuropathology, National Institute of Mental Health And Neurosciences (NIMHANS), Bengaluru, 560029, India.
Gautham ArunachalDepartment of Human Genetics, National Institute of Mental Health And Neurosciences (NIMHANS), Bengaluru, 560029, India.
Atchayaram NaliniDepartment of Neurology, National Institute of Mental Health And Neurosciences (NIMHANS), Bengaluru, 560029, India. atchayaramnalini@yahoo.co.in.ORCID http://orcid.org/0000-0001-9791-3639
Mohammed FaruqCSIR-Institute of Genomics and Integrative Biology, Mall Road, Delhi, 110025, India. faruq.mohd@igib.in.
Institute of Genomics and Integrative Biology · INNational Institute of Mental Health and Neurosciences · INChildren's Hospital of Eastern Ontario · CAEssen University Hospital · DENewcastle University · GBUniversity of Cambridge · GBUniversity of Ottawa · CA

Funding

CIHR FDN-167281Medical Research Council G1000848Medical Research Council MR/N010035/1Medical Research Council MR/N025431/1Medical Research Council MR/N025431/2Medical Research Council MR/V009346/1
6 · The paper itself

Abstract

Twelve patients from seven unrelated South Indian families with a limb-girdle muscular dystrophy-congenital myasthenic syndrome (LGMD/CMS) phenotype and recessive inheritance underwent deep clinical phenotyping, electrophysiological evaluation, muscle histopathology, and next-generation sequencing/Sanger sequencing-based identification of the genetic defect. Homozygosity mapping was performed using high-throughput genome-wide genotyping for mapping the mutation and to evaluate the founder effect. The age of disease onset among patients ranged from childhood to 40 years of age. The key clinical manifestations observed were progressive fatigable limb-girdle weakness, muscle hypertrophy/atrophy, and preferential weakness in a dystrophic pattern. The ages at last follow-up ranged from 30 to 64 years; nine were independently ambulant, two required assistance, and one was wheelchair-bound. Lower limb muscle MRI showed varying degrees of fat replacement in the glutei, hamstrings, anterior leg muscles, and medial gastrocnemius. All patients showed significant decrement on repetitive nerve stimulation (RNS). Muscle biopsy in 7 patients revealed varying degrees of dystrophic and neurogenic changes. Treatment with pyridostigmine and/or salbutamol resulted in variable improvement in 10 patients. Genetic analysis showed an identical homozygous GMPPB mutation c.1000G > A (p.Asp334Asn) in all affected patients. A region of homozygosity (6Mbp) was observed flanking the c.1000G > A change in carrier chromosomes. This study identifies c.1000G > A in GMPPB as a common founder mutation in an ethnic community of South Indian descent with milder yet variable degree of clinical presentation of GMPPB-associated LGMD-CMS.

Indexed as

AdultChildFemaleGenetic TestingHumansMagnetic Resonance ImagingMaleMiddle AgedMusclesMuscular Dystrophies, Limb-GirdleMutationMyasthenic Syndromes, CongenitalNucleotidyltransferasesPhenotypemannose 1-phosphate guanylyltransferaseNucleotidyltransferasesFounder mutationLimb girdle muscular dystrophy-congenital myasthenic syndrome (LGMD/CMS)Muscle diseaseMuscle MRINeuromuscular disorders

Identifiers

PMID34333724
OpenAlexW3190477891

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.